EUVIMEDEUVIMED entdecken
Crossref

Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ

Chloé Paris iD, Raphaëlle Curmin, Laurie Gouillon, Caroline Giboin, Yann De Rycke, Hervé Bachelez, Nathalie Beneton, Marie Beylot-Barry iD, Alain Dupuy iD, Pascal Joly iD, Emmanuel Mahé iD, Carle Paul und 7 weitere

Journal of the European Academy of Dermatology and Venereology · 2026-02 · 40 (2) · 265-273

DOI: 10.1111/jdv.70044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 30.09.2025. Verfasst von Chloé Paris und 18 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologie, HCL, Hôpital Edouard Herriot, Lyon, France. Hauptthemen laut MEDLINE: Methotrexate, Psoriasis, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Agence Nationale de Sécurité du Médicament et des Produits de Santé, AbbVie, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are limited data on the impact of the route of administration of methotrexate (MTX) on drug survival in psoriasis.

Objective

To evaluate the impact of the initial route of administration of MTX (monotherapy) on drug survival in patients with moderate to severe skin psoriasis. Materials and Methods A prospective cohort study based on the Psobioteq registry, included from July 2012 to January 2023, patients with plaque, erythrodermic or guttate psoriasis, naive to MTX, biologics and apremilast, who initiated MTX monotherapy. Factors associated with drug survival were identified using Kaplan–Meier curves and Cox regression analyses.

Results

In total, 406 patients were included, 58.1% received MTX per os (MTX‐PO) and 41.9% subcutaneously (MTX‐SC). At MTX initiation, the median PASI score was 11, and 67.3% had DLQI ≥6. Adjusted drug survival did not statistically differ according to the route of administration ( p = 0.15).

Limitations

Limited number of patients leading to a potential lack of power. Residual confounding cannot be waived due to the observational nature of the data.

Conclusions

Overall MTX survival did not significantly differ according to the route of administration. However, with MTX‐SC, the hazard of discontinuation for ineffectiveness was lower and of discontinuation for intolerance was higher than with MTX‐PO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexatePsoriasisDermatologic AgentsHumansFemaleMaleMiddle AgedProspective StudiesAdultRegistriesAgedDrug Administration RoutesSeverity of Illness Index

Stichwörter der Autor:innen

drug survivalmethotrexatepsoriasis

Substanzen

MethotrexateDermatologic Agents

Autor:innen und Institutionen

  • Dermatologie, HCL, Hôpital Edouard Herriot, Lyon, France.
  • Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Paris, France.
  • Dermatologie, AP-HP, Hôpital Saint-Louis, Paris, France.
  • Dermatologie, CHU Le Mans, Le Mans, France.
  • Dermatologie, CHU Bordeaux, Hôpital Saint-André, Bordeaux, France.
  • Dermatologie, CHU Rennes, Hôpital Pontchaillou, Rennes, France.

ORCID-Profile: Chloé Paris, Marie Beylot-Barry, Alain Dupuy, Pascal Joly, Emmanuel Mahé, Émilie Sbidian, Olivier Chosidow, Denis Jullien

Förderung

  • Agence Nationale de Sécurité du Médicament et des Produits de Santé
  • AbbVie
  • Pfizer
  • Ministère de la Santé
  • Janssen Pharmaceutica
  • Amgen
  • Novartis
  • Celgene

Zitieren

APA

Paris, C., Curmin, R., Gouillon, L., Giboin, C., De Rycke, Y., Bachelez, H., Beneton, N., Beylot-Barry, M., Dupuy, A., Joly, P., Mahé, E., Paul, C., Richard, M. A., Sbidian, É., Viguier, M., Chosidow, O., Tubach, F., Jullien, D., & PSOBIOTEQ study group (2026). Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ. Journal of the European Academy of Dermatology and Venereology, 40(2), 265-273. https://doi.org/10.1111/jdv.70044

Vancouver

Paris C, Curmin R, Gouillon L, Giboin C, De Rycke Y, Bachelez H, et al. Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ. Journal of the European Academy of Dermatology and Venereology. 2026;40(2):265-273. doi:10.1111/jdv.70044

BibTeX
@article{Paris2026,
  author = {Paris, Chloé and Curmin, Raphaëlle and Gouillon, Laurie and Giboin, Caroline and De Rycke, Yann and Bachelez, Hervé and Beneton, Nathalie and Beylot-Barry, Marie and Dupuy, Alain and Joly, Pascal and Mahé, Emmanuel and Paul, Carle and Richard, Marie-Aleth and Sbidian, Émilie and Viguier, Manuelle and Chosidow, Olivier and Tubach, Florence and Jullien, Denis and PSOBIOTEQ study group, PSOBIOTEQ study group},
  title = {Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {2},
  pages = {265--273},
  doi = {10.1111/jdv.70044}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche